Supplementary Appendix

Supplement to: Antoniou T, Zheng H, Singh S, Juurlink DN, Mamdani MM, Gomes T. Statins and the risk of herpes zoster: a population-based study

Covariates use in propensity score matching

Medication use in previous year

Oral corticorsteroids

Prednisone, prednisolone, dexamethasone, methylprednisolone, triamcinolone, hydrocortisone

Immune modulating drugs

adalimubab, methotrexate, azathioprine, mercaptopurine, cyclosporine, cyclophosphamide, tacrolimus, sirolimus, everolimus, daclizumab, efalizumabab, glatiramer, lenalidomide, mycophenolate, chlorambucil, leflunomide, abatacept, etanercept, infliximab, rituximab, adalimubab

Number of prescription drugs in past year

Socioeconomic status (income quintiles)

Charlson co-morbidity index

Chronic kidney disease in past year

Medical conditions and procedures in previous 5 years

Myocardial infarction

Angina

Hypertension

Stroke/transient ischemic attack

Systemic malignancy (including leukemia and lymphoma)

Ulcerative colitis

Crohn's disease

Rheumatoid arthritis

Systemic lupus erythematosus

Human immunodeficiency virus infection

Coronary arter bypass grafting

Supplemental Table 1: Distribution of statin users at baseline according to type and dose of statin

	Low dose ^a	Moderate dose ^b	High dose ^c
Statin			
Atorvastatin	194,897 (39.4%)	112,613 (22.8%)	5,649 (63.3%)
Cerivastatin	4,475 (0.9%)	5,542 (1.1%)	297 (0.06%)
Fluvastatin	7,098 (1.4%)	0 (0%)	0 (0%)
Lovastatin	7,953 (1.6%)	0 (0%)	0 (0%)
Pravastatin	44,936 (9.1%)	0 (0%)	0 (0%)
Rosuvastatin	18,912 (3.8%)	82,658 (16.7%)	1,351 (0.3%)
Simvastatin	8,104 (1.6%)	166 (0.03%)	0 (0%)

Supplemental Table 2: Number of statin users that change doses during follow-up

	Number (%)
Low dose to moderate dose	40,629 (8.2%)
Moderate dose to high dose	5,834 (1.2%)
Low dose to high dose	749 (0.2%)
Remained on baseline dose	447,439 (90.5%)